TY - JOUR
T1 - Effect of Lactobacillus gasseri BNR17 on irritable bowel syndrome
T2 - a randomized, double-blind, placebo-controlled, dose-finding trial
AU - Kim, Ji Yeon
AU - Park, Yeo Jin
AU - Lee, Hyo Jin
AU - Park, Min Young
AU - Kwon, Oran
N1 - Funding Information:
This study was supported by a Bio-Synergy Research Project (2012M3A9C4048761) of the National Research Foundation funded by the Ministry of Science, ICT and Future Planning, Republic of Korea. The authors declare that they have no conflict of interest.
Publisher Copyright:
© 2017, The Korean Society of Food Science and Technology and Springer Science+Business Media B.V., part of Springer Nature.
PY - 2018/6/1
Y1 - 2018/6/1
N2 - Lactobacillus gasseri BNR17 is a strain isolated from human breast milk. The objective of this randomized, double-blind, placebo-controlled, and preliminary dose-finding trial was to find the effective dose and evaluate the effect of Lb. gasseri BNR17 on irritable bowel syndrome (IBS) symptoms. A total of 55 volunteers aged over 20 years with body mass index over 23 kg/m2 were randomized to intake a placebo, low-dose (BNR-L, 2 × 108 CFU/day), intermediate-dose (BNR-M, 2 × 109 CFU/day), or high-dose BNR (BNR-H, 2 × 5 × 109 CFU/day) for four weeks. Questionnaire for IBS symptoms scores and Lb. gasseri BNR17 in feces were assessed at the beginning and end of the trial. Among IBS symptoms scores, abdominal pain score was significantly reduced in BNR-H group. Lb. gasseri BNR17 was detected in all intake groups except placebo. In the preliminary study, Lb. gasseri BNR17 was confirmed to have probiotic properties.
AB - Lactobacillus gasseri BNR17 is a strain isolated from human breast milk. The objective of this randomized, double-blind, placebo-controlled, and preliminary dose-finding trial was to find the effective dose and evaluate the effect of Lb. gasseri BNR17 on irritable bowel syndrome (IBS) symptoms. A total of 55 volunteers aged over 20 years with body mass index over 23 kg/m2 were randomized to intake a placebo, low-dose (BNR-L, 2 × 108 CFU/day), intermediate-dose (BNR-M, 2 × 109 CFU/day), or high-dose BNR (BNR-H, 2 × 5 × 109 CFU/day) for four weeks. Questionnaire for IBS symptoms scores and Lb. gasseri BNR17 in feces were assessed at the beginning and end of the trial. Among IBS symptoms scores, abdominal pain score was significantly reduced in BNR-H group. Lb. gasseri BNR17 was detected in all intake groups except placebo. In the preliminary study, Lb. gasseri BNR17 was confirmed to have probiotic properties.
KW - Irritable bowel syndrome
KW - Lactobacillus gasseri BNR17
KW - Probiotics
UR - http://www.scopus.com/inward/record.url?scp=85047662923&partnerID=8YFLogxK
U2 - 10.1007/s10068-017-0296-7
DO - 10.1007/s10068-017-0296-7
M3 - Article
AN - SCOPUS:85047662923
SN - 1226-7708
VL - 27
SP - 853
EP - 857
JO - Food Science and Biotechnology
JF - Food Science and Biotechnology
IS - 3
ER -